Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

被引:10
|
作者
Matsuda, Satoru [1 ]
Kawakubo, Hirofumi [1 ]
Tsuji, Takayuki [1 ]
Aoyama, Junya [1 ]
Hirata, Yuki [1 ]
Takemura, Ryo [2 ]
Mayanagi, Shuhei [1 ]
Irino, Tomoyuki [1 ]
Fukuda, Kazumasa [1 ]
Nakamura, Rieko [1 ]
Takeuchi, Hiroya [3 ]
Kitagawa, Yuko [1 ]
机构
[1] Keio Univ, Dept Surg, Sch Med, Tokyo, Japan
[2] Keio Univ Hosp, Biostat Unit, Clin & Translat Res Ctr, Tokyo, Japan
[3] Hamamatsu Univ Sch Med, Dept Surg, Hamamatsu, Shizuoka, Japan
关键词
LOCALLY ADVANCED ESOPHAGEAL; PREOPERATIVE THERAPY; CANCER; CHEMORADIOTHERAPY; CISPLATIN; DOCETAXEL; SURGERY;
D O I
10.1245/s10434-021-11009-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To appropriately adopt the organ preservation approach, including subsequent chemoradiotherapy (CRT) in patients who respond to neoadjuvant chemotherapy (NAC), the distribution of residual disease, including pathological lymph nodes (LNs) and recurrence site, needs to be recognized preoperatively. This study was designed to evaluate whether endoscopic response evaluation can predict residual tumor distribution. Methods Patients with esophageal squamous cell carcinoma who underwent transthoracic esophagectomy (TTE) were retrospectively reviewed. Endoscopic responder (ER) to NAC was defined according to primary tumor endoscopic findings. Recurrence-free survival (RFS), overall survival (OS), and residual tumor patterns were compared between groups. Results Of 193 patients, 40 (20%) were classified as ER. ERs showed significantly better RFS and OS. The pN location was found within the primary tumor and cN field in 88% of ERs, which was significantly higher than non-ERs at 63% (p = 0.004). Furthermore, the postoperative recurrence incidence in the distant organ was significantly lower in the ERs than the non-ERs (8%, 32%, respectively, p = 0.002). Residual disease, including postoperative initial recurrence, existed within the same field as the primary tumor and cN in 88% of ERs, significantly higher than 42% in the non-ERs (p < 0.001). Conclusions Endoscopic response evaluation can preoperatively predict distribution of residual tumors after NAC, which could help radiation field selection in subsequent definitive CRT when patients prefer to omit TTE. Along with improvements in NAC response rate, this could facilitate organ preservation in patients who respond to NAC.
引用
收藏
页码:2673 / 2680
页数:8
相关论文
共 50 条
  • [41] The Role of Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Patients with Pathological Positive Lymph Nodes After Neoadjuvant Chemotherapy Followed by Esophagectomy: a Single Institute Retrospective Analysis
    Imai, Takeharu
    Tanaka, Yoshihiro
    Sato, Yuta
    Mase, Junichi
    Suetsugu, Tomonari
    Fukada, Masahiro
    Yasufuku, Itaru
    Iwata, Yoshinori
    Mori, Ryutaro
    Imai, Hisashi
    Kato, Takazumi
    Okumura, Naoki
    Matsuhashi, Nobuhisa
    Takahashi, Takao
    Futamura, Manabu
    Yoshida, Kazuhiro
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2021, 12 (04) : 776 - 784
  • [42] Multiple diffusion models for predicting pathologic response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy
    Bai, Bingmei
    Cui, Long
    Chu, Funing
    Wang, Zhaoqi
    Zhao, Keke
    Wang, Shuting
    Wang, Shaoyu
    Yan, Xu
    Wang, Mengzhu
    Kamel, Ihab R.
    Yang, Guang
    Qu, Jinrong
    ABDOMINAL RADIOLOGY, 2024, 49 (12) : 4216 - 4226
  • [43] Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma
    Matsuda, S.
    Tsubosa, Y.
    Sato, H.
    Takebayashi, K.
    Kawamorita, K.
    Mori, K.
    Niihara, M.
    Tsushima, T.
    Yokota, T.
    Onozawa, Y.
    Yasui, H.
    Takeuchi, H.
    Kitagawa, Y.
    DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [44] Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma: A pooled analysis of randomized clinical trials
    Yang, Yang
    Shao, Rongjun
    Cao, Xiufeng
    Chen, Mengyuan
    Gong, Wangang
    Ying, Hangjie
    Song, Ge
    You, Guangxian
    Qiu, Guoqin
    Chen, Qixun
    Ji, Yongling
    Xu, Dong
    RADIOTHERAPY AND ONCOLOGY, 2024, 200
  • [45] Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma
    Nakashima, Yuichiro
    Saeki, Hiroshi
    Hu, Qingjiang
    Tsuda, Yasuo
    Hisamatsu, Yuichi
    Ando, Koji
    Oki, Eiji
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2018, 38 (12) : 6809 - 6814
  • [46] Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Miyata, Hiroshi
    Yamasaki, Makoto
    Miyazaki, Yasuhiro
    Takahashi, Tsuyoshi
    Kurokawa, Yukinori
    Nakajima, Kiyokazu
    Takiguchi, Shuji
    Mori, Masaki
    Doki, Yuichiro
    ANNALS OF SURGERY, 2015, 262 (02) : 280 - 285
  • [47] Radiotherapy for patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy
    Kong, Yue
    Su, Miaoyi
    Fang, Jun
    Chen, Mengyuan
    Zheng, Chao
    Jiang, Youhua
    Tao, Kaiyi
    Wang, Changchun
    Qiu, Guoqin
    Ji, Yongling
    Wang, Yuezhen
    Yang, Yang
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [48] Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma
    Hiraki, Yoko
    Kimura, Yutaka
    Imano, Motohiro
    Kato, Hiroaki
    Iwama, Mitsuru
    Shiraishi, Osamu
    Yasuda, Atsushi
    Shinkai, Masayuki
    Makino, Tomoki
    Motoori, Masaaki
    Yamasaki, Makoto
    Miyata, Hiroshi
    Satou, Takao
    Satoh, Taroh
    Furukawa, Hiroshi
    Yano, Masahiko
    Doki, Yuichiro
    Yasuda, Takushi
    SURGERY TODAY, 2021, 51 (01) : 118 - 126
  • [49] Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery
    Hamai, Yoichi
    Emi, Manabu
    Ibuki, Yuta
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Ohsawa, Manato
    Hirohata, Ryosuke
    Kitasaki, Nao
    Okada, Morito
    ANTICANCER RESEARCH, 2022, 42 (12) : 6037 - 6045
  • [50] Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery
    Kitasaki, Nao
    Hamai, Yoichi
    Emi, Manabu
    Kurokawa, Tomoaki
    Yoshikawa, Toru
    Hirohata, Ryosuke
    Ohsawa, Manato
    Okada, Morithito
    IN VIVO, 2022, 36 (06): : 2852 - 2860